Toxicity of nanomaterials to the eye

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 2, Issue 4, 2010, Pages 317-333

  Prow, Tarl W ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNE CELLS; NANO-MATERIALS; NANOMEDICINES; NEURAL CELLS; OCULAR DELIVERY; OCULAR DISEASE; QUALITY OF LIFE; RAPID DEVELOPMENT; RESEARCH OPPORTUNITIES; TISSUE TYPES; TOXIC EFFECT;

BLOOD VESSELS; DRUG DELIVERY; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; NANOSTRUCTURED MATERIALS;

TOXICITY;

ALBUMIN; ALKALINE PHOSPHATASE; AMINO ACID; BETA GALACTOSIDASE; CHITOSAN; CYCLOSPORIN A; DENDRIMER; EUDRAGIT; GANCICLOVIR; GATIFLOXACIN; GELATIN; GOLD; HYALURONIC ACID; INDOMETACIN; IRON OXIDE; MACROGOL; PILOCARPINE; POLYGLACTIN; POLYLACTIC ACID; SOLID LIPID NANOPARTICLE; SUPERPARAMAGNETIC IRON OXIDE; TOBRAMYCIN; VASCULOTROPIN;

ABSORPTION; CELL STRUCTURE; CELL VIABILITY; CONJUNCTIVA; CONTROLLED RELEASE FORMULATION; CORNEA; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; DRUG STABILITY; DRUG TOLERABILITY; EYE; FOOD AND DRUG ADMINISTRATION; FREEZE DRYING; GAS PERMEABILITY; GENE TARGETING; HISTOLOGY; HUMAN; IN VITRO STUDY; INFLAMMATION; MEMBRANE PERMEABILITY; NERVE CELL; NERVE FIBER; NONHUMAN; PH; PIGMENT EPITHELIUM; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; RABBIT; RETINA; RETINA BIPOLAR GANGLION CELL; RETINA INNER PLEXIFORM LAYER; RETINA NEOVASCULARIZATION; REVIEW; SERUM; SKIN IRRITATION;

ANIMALS; CELLS, CULTURED; CORNEA; DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE; NANOSTRUCTURES; OPHTHALMIC SOLUTIONS; RABBITS; RATS;

EID: 77955478307     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.65     Document Type: Review

References (66)

1. Calvo P, Vila-Jato JL, Alonso MJ. Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug carriers. J Pharm Sci 1996, 85:530-536.
2. Badawi AA, El-Laithy HM, El Qidra RK, El Mofty H, El dally M. Chitosan based nanocarriers for indomethacin ocular delivery. Arch Pharm Res 2008, 31:1040-1049.
3. Prow TW, Bhutto I, Kim SY, Grebe R, Merges C, et al. Ocular nanoparticle toxicity and transfection of the retina and retinal pigment epithelium. Nanomedicine 2008, 4:340-349.
4. de la Fuente M, Seijo B, Alonso MJ. Novel hyaluronic acid-chitosan nanoparticles for ocular gene therapy. Invest Ophthalmol Vis Sci 2008, 49:2016-2024.
5. Diebold Y, Jarrin M, Saez V, Carvalho EL, Orea M, et al. Ocular drug delivery by liposome - chitosan nanoparticle complexes (LCS-NP). Biomaterials 2007, 28:1553-1564.
6. Enriquez de Salamanca A, Diebold Y, Calonge M, Garcia-Vazquez C, Callejo S, et al. Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and in vivo tolerance. Invest Ophthalmol Vis Sci 2006, 47:1416-1425.
7. de Campos AM, Diebold Y, Carvalho EL, Sanchez A, Alonso MJ. Chitosan nanoparticles as new ocular drug delivery systems: in vitro stability, in vivo fate, and cellular toxicity. Pharm Res 2004, 21:803-810.
8. Qaddoumi MG, Ueda H, Yang J, Davda J, et al. The characteristics and mechanisms of uptake of PLGA nanoparticles in rabbit conjunctival epithelial cell layers. Pharm Res 2004, 21:641-648.
9. Fei WL, Chen JQ, Yuan J, Quan DP, Zhou SY. Preliminary study of the effect of FK506 nanosphericsuspension eye drops on rejection of penetrating keratoplasty. J Ocul Pharmacol Ther 2008, 24:235-244.
10. Xu J, Wang Y, Li Y, Yang X, Zhang P, et al. Inhibitory efficacy of intravitreal dexamethasone acetate-loaded PLGA nanoparticles on choroidal neovascularization in a laser-induced rat model. J Ocul Pharmacol Ther 2007, 23:527-540.
11. Vega E, Egea MA, Valls O, Espina M, Garcia ML. Flurbiprofen loaded biodegradable nanoparticles for ophtalmic administration. J Pharm Sci 2006, 95:2393-2405.
12. Bejjani RA, BenEzra D, Cohen H, Rieger J, Andrieu C, et al. Nanoparticles for gene delivery to retinal pigment epithelial cells. Mol Vis 2005, 11:124-132.
13. Agnihotri SM, Vavia PR. Diclofenac-loaded biopolymeric nanosuspensions for ophthalmic application. Nanomedicine 2009, 5:90-95.
14. Bucolo C, Maltese A, Maugeri F, Busa B, Puglisi G, et al. Eudragit RL100 nanoparticle system for the ophthalmic delivery of cloricromene. J Pharm Pharmacol 2004, 56:841-846.
15. Pignatello R, Bucolo C, Puglisi G. Ocular tolerability of Eudragit RS100 and RL100 nanosuspensions as carriers for ophthalmic controlled drug delivery. J Pharm Sci 2002, 91:2636-2641.
16. Adibkia K, Siahi Shadbad MR, Nokhodchi A, Javadzedeh A, Barzegar-Jalali M, et al. Piroxicam nanoparticles for ocular delivery: physicochemical characterization and implementation in endotoxin-induced uveitis. J Drug Target 2007, 15:407-416.
17. Bucolo C,Maltese A, Puglisi G, Pignatello R. Enhanced ocular anti-inflammatory activity of ibuprofen carried by an Eudragit RS100 nanoparticle suspension. Ophthalmic Res 2002, 34:319-323.
18. Pignatello R, Bucolo C, Ferrara P, Maltese A, Puleo A, et al. Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J Pharm Sci 2002, 16:53-61.
19. Pignatello R, Bucolo C, Spedalieri G,Maltese A, Puglisi G. Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials 2002, 23:3247-3255.
20. Prow TW, Bhutto I, Grebe R, Uno K, Merges C, et al. Nanoparticle- delivered biosensor for reactive oxygen species in diabetes. Vision Res 2008, 48:478-485.
21. Prow T, Smith JN, Grebe R, Salazar JH,Wang N, et al. Construction, gene delivery, and expression of DNA tethered nanoparticles. Mol Vis 2006, 12:606-615.
22. Wolf NB, Kuchler S, Radowski MR, Blaschke T, Kramer KD, et al. Influences of opioids and nanoparticles on in vitro wound healing models. Eur J Pharm Biopharm 2009, 73:34-42.
23. Gokce EH, Sandri G, Bonferoni MC, Rossi S, Ferrari, F, et al. Cyclosporine A loaded SLNs: evaluation of cellular uptake and corneal cytotoxicity. Int J Pharm 2008, 364:76-86.
24. Cavalli R, Gasco MR, Chetoni P, Burgalassi S, Saettone MF. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm 2002, 238:241-245.
25. Merodio M, Irache JM, Valamanesh F, Mirshahi M. Ocular disposition and tolerance of ganciclovir-loaded albumin nanoparticles after intravitreal injection in rats. Biomaterials 2002, 23:1587-1594.
26. Mo Y, Barnett ME, Takemoto D, Davidson H, Kompella UB. Human serum albumin nanoparticles for efficient delivery of Cu, Zn superoxide dismutase gene. Mol Vis 2007, 13:746-757.
27. Kim H, Robinson SB, Csaky KG. Investigating the movement of intravitreal human serum albumin nanoparticles in the vitreous and retina. Pharm Res 2009, 26:329-337.
28. Jani PD, Singh N, Jenkins C, Raghava S, Mo Y, et al. Nanoparticles sustain expression of Flt intraceptors in the cornea and inhibit injury-induced corneal angiogenesis. Invest Ophthalmol Vis Sci 2007, 48:2030-2036.
29. Ratto F, Matteini P, Rossi F, Menabuoni L, Tiwari N, et al. Photothermal effects in connective tissues mediated by laser-activated gold nanorods. Nanomedicine 2009, 5:143-151.
30. Cai X, Nash Z, Conley SM, Fliesler SJ, Cooper MJ, et al. A partial structural and functional rescue of a retinitis pigmentosa model with compacted DNA nanoparticles. PLoS ONE 2009, 4:e5290.
31. Farjo R, Skaggs J, Quiambao AB, Cooper MJ, Naash MI. Efficient non-viral ocular gene transfer with compacted DNA nanoparticles. PLoS ONE 2006, 1:e38.
32. Marano RJ, Toth I, Wimmer N, Brankov M, Rakoczy PE. Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: a long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity. Gene Ther 2005, 12:1544-1550.
33. Parekh HS, Marano RJ, Rakoczy EP, Blanchfield J, Toth I. Synthesis of a library of polycationic lipid core dendrimers and their evaluation in the delivery of an oligonucleotide with hVEGF inhibition. Bioorg Med Chem 2006, 14:4775-4780.
34. Sakai T, Kuno N, Takamatsu F, Kimura E, Kohno H, et al. Prolonged protective effect of basic fibroblast growth factor-impregnated nanoparticles in royal college of surgeons rats. Invest Ophthalmol Vis Sci 2007, 48:3381-3387.
35. Bakri SJ, Pulido JS, Mukherjee P, Marler RJ, Mukhopadhyay D. Absence of histologic retinal toxicity of intravitreal nanogold in a rabbit model. Retina 2008, 28:147-149.
36. Roberts JE, Wielgus AR, Boyes WK, Andley U, Chignell CF. Phototoxicity and cytotoxicity of fullerol in human lens epithelial cells. Toxicol Appl Pharmacol 2008, 228:49-58.
37. Hashida N, Ohguro N, Yamazaki N, Arakawa Y, Oiki E, et al. High-efficacy site-directed drug delivery system using sialyl - Lewis X conjugated liposome. Exp Eye Res 2008, 86:138-149.
38. Tong YC, Chang SF, Liu CY, Kao WW, Huang CH, et al. Eye drop delivery of nano-polymeric micelle formulated genes with cornea-specific promoters. J Gene Med 2007, 9:956-966.
39. Sakai T, Kohno H, Ishihara T, Higaki M, Saito S, et al. Treatment of experimental autoimmune uveoretinitis with poly(lactic acid) nanoparticles encapsulating betamethasone phosphate. Exp Eye Res 2006, 82:657-663.
40. Bourges JL, Gautier SE, Delie F, Bejjani RA, Jeanny JC, et al. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest Ophthalmol Vis Sci 2003, 44:3562-3569.
41. Giannavola C, Bucolo C, Maltese A, Paolino D, Vandelli MA, et al. Influence of preparation conditions on acyclovir-loaded poly-d,l-lactic acid nanospheres and effect of PEG coating on ocular drug bioavailability. Pharm Res 2003, 20:584-590.
42. de Kozak Y, Andrieux K, Villarroya H, Klein C, Thillaye-Goldenberg B, et al. Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis. Eur J Immunol 2004, 34:3702-3712.
43. De TK, Bergey EJ, Chung SJ, Rodman DJ, Bharali DJ, et al. Polycarboxylic acid nanoparticles for ophthalmic drug delivery: an ex vivo evaluation with human cornea. J Microencapsul 2004, 21:841-855.
44. Calvo P, Vila-Jato JL, Alonso MJ. Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug carriers. J Pharm Sci 1996, 85:530-536.
45. Gupta AK, Madan S, Majumdar DK, Maitra A. Ketorolac entrapped in polymeric micelles: preparation, characterisation and ocular anti-inflammatory studies. Int J Pharm 2000, 209:1-14.
46. Hsiue GH, Hsu SH, Yang CC, Lee SH, Yang IK. Preparation of controlled release ophthalmic drops, for glaucoma therapy using thermosensitive poly-N-isopropylacrylamide. Biomaterials 2002, 23:457-462.
47. Amrite, AC., Kompella UB. Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration. J Pharm Pharmacol 2005, 57:1555-1563.
48. Cheng L, Anglin E, Cunin F, Kim D, Sailor MJ, et al. Intravitreal properties of porous silicon photonic crystals: a potential self-reporting intraocular drug-delivery vehicle. Br J Ophthalmol 2008, 92:705-711.
49. Yamamoto S, Manabe N, Fujioka K, Hoshino A, Yamamoto K. Visualizing vitreous using quantum dots as imaging agents. IEEE Trans Nanobioscience 2007, 6:94-98.
50. Roizenblatt R, Weiland JD, Carcieri S, Qiu G, Behrend M, et al. Nanobiolistic delivery of indicators to the living mouse retina. J Neurosci Methods 2006, 153:154-161.
51. Kaur IP, Kanwar M. Ocular preparations: the formulation approach. Drug Devel Ind Pharm 2002, 28:473-493.
52. VanSantvliet L, Ludwig A. The influence of penetration enhancers on the volume instilled of eye drops. Eur J Pharm Biopharm 1998, 45:189-198.
53. Zhang W, Prausnitz MR, Edwards A. Modal of transient drug diffusion across cornea. J Control Release 2004, 99:241-258.
54. Dornish M, Hagan A, Hansson E, Pecheur C, Verdier F, et al. Safety of protasan: ultrapure chitosan salts for biomedical and pharmaceutical use. Seventh International Conference on Chitin and Chitosan, Lyon, France, 1997.
55. De Campos AM, Sanchez A, Alonso MJ. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int J Pharm 2001, 224:159-168.
56. Felt O, Furrer P, Mayer JM, Plazonnet B, Buri P, et al. Topical use of chitosan in ophthalmology: tolerance assessment and evaluation of precorneal retention. Int J Pharm 1999, 180:185-193.
57. de la Fuente M, Seijo B, Alonso MJ. Bioadhesive hyaluronan - chitosan nanoparticles can transport genes across the ocular mucosa and transfect ocular tissue. Gene Ther 2008, 15:668-676.
58. Mao HQ, Roy K, Troung-Le VL, Janes KA, Lin KY, et al. Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J Control Release 2001, 70:399-421.
59. Taylor HF. Vitamin preparations and methods of making same. US Patent 2,183,053 (12 December); 1938.
60. Kulkarni RK, Moore EG, Hegyelli AF, Leonard F. Biodegradable poly(lactic acid) polymers. J Biomed Mater Res 1971, 5:169-181.
61. Bhutto IA, Kim SY, McLeod S, Merges C, Fukai N, et al. Retinal and choroidal localization of collagen XVIII and the endostatin portion of collagen XVIII in aged human control and in age related macular degeneration subjects. Invest Ophthalmol Vis Sci 2004, 45:1544-1552.
62. Joshi MD, Müller RH. Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm 2009, 71:161-172. Epub 2008 Sep 13.
63. Cavalli R, Morel S, Gasco MR, Saettone MF, Chetoni P. Preparation and evaluation in vitro of colloidal lipospheres containing pilocarpine as ion-pair. Int. J. Pharm 1995, 117:243-246.
64. del Pozo-Rodriguez A, Delgado D, Solinis MA, Gascon AR, Pedraz JL. Solid lipid nanoparticles for retinal gene therapy: transfection and intracellular trafficking in RPE cells. Int J Pharm 2008, 360:177-183.
65. Rabinovich-Guilatt L, Couvreur P, Lambert G, Dubernet C. Cationic vectors in ocular drug delivery. J Drug Target 2004, 12:623-633.
66. Panessa-Warren BJ, Maye MM, Warren JB, Crosson KM. Single walled carbon nanotube reactivity and cytotoxicity following extended aqueous exposure. Environ Pollut 2009, 157:1140-1151. Epub 2009 Feb 7.